KR Choksey's research report on Alembic Pharmaceutical. Alembic Pharma’s revenue missed our estimate slightly due to weak growth in India, Ex-US (other than the US market), and API segments. However, EBITDA beat our estimates due to cost optimization measures and better utilization. Currently, the stock is trading at PE multiples of 28.6x/21.7x based on FY25E/FY26E EPS estimates, respectively.
Open FlipBitcoin To Stay Under $75K Until the US Election or Fed Cuts Rates, Says Novogratz Bitcoin's price could remain stuck between $55,000 and $75,000 for the next few months, according to Mike Novogratz, CEO of crypto investment firm Galaxy Digital. Novogratz said on Galaxy's Q1 earnings call that he sees Bitcoin consolidating in that range until either the upcoming US presidential elections.
Open FlipShares of Eli Lilly (NYSE: LLY) are up by a shocking 309% over the last three years, and, as smart investors know, a lot of that gain is attributable to just two words. Both of those words are the names of the company's rising-star medicines. And the projections for the future growth prompted by both of those medicines are likely to shock even the optimists.
Open Flip